In recent years, legislators, enforcement agencies, and private plaintiffs have taken aim at the prices of pharmaceutical products.
Federal legislation and a growingly complex web of state drug-pricing laws have generated new and challenging competition questions for companies at every level of the pharmaceutical distribution chain. At the same time, federal and state enforcers have initiated investigations, and even pursued litigation, targeting a host of business practices related to the pricing of pharmaceutical products. Private plaintiffs have followed suit, relying on criticisms of pharmaceutical prices to support aggressive litigation strategies and novel causes of action.
White & Case's Antitrust/Competition Group and Pharmaceuticals & Healthcare Industry Group tracks developments in competition and pharmaceutical-pricing policy closely, with a specific focus on potential investigations and litigation.